SCHEMBL1015633

SCHEMBL1015633

O=C(COCC(=O)Nc1ccccc1-c1ccncc1)Nc1ccc(Cl)cc1C(=O)O

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SERPINE1 P05121 5/20 0.56
POLB P06746 3/20 0.53
G6PD P11413 1/20 0.53
ALDH1A1 P00352 5/20 0.50
KDM4E B2RXH2 4/20 0.49
GAA P10253 1/20 0.49
MAPT P10636 2/20 0.48
NPY1R P25929 1/20 0.47
NPY2R P49146 1/20 0.47
NPSR1 Q6W5P4 1/20 0.46
TP53 P04637 1/20 0.46
TRPM4 Q8TD43 1/20 0.46
MEN1 O00255 1/20 0.45
MAPK1 P28482 1/20 0.45
KMT2A Q03164 1/20 0.45
HSD17B10 Q99714 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
LMNA P02545 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1016123 0.99 SERPINE1 (0.55) SERPINE1POLBG6PDALDH1A1KDM4E
SCHEMBL1016003 0.89 ALDH1A1 (0.47) SERPINE1POLBALDH1A1KDM4EGAA
SCHEMBL1013461 0.87 SERPINE1 (0.56) SERPINE1POLBG6PDALDH1A1KDM4E
SCHEMBL1015619 0.86 SERPINE1 (0.49) SERPINE1POLBG6PDALDH1A1KDM4E
SCHEMBL1014958 0.84 SERPINE1 (0.55) SERPINE1POLBG6PDALDH1A1KDM4E
SCHEMBL1016300 0.83 SERPINE1 (0.54) SERPINE1POLBG6PDKDM4EGAA
SCHEMBL1016298 0.83 SERPINE1 (0.54) SERPINE1POLBG6PDALDH1A1KDM4E
SCHEMBL1796212 0.79 TP53 (0.69) SERPINE1POLBALDH1A1GAAMAPT
SCHEMBL1016077 0.78 POLB (0.60) SERPINE1POLBG6PDALDH1A1KDM4E
SCHEMBL1797569 0.78 SERPINE1 (0.56) SERPINE1POLBG6PDALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2990057-B1 PAI-1 INHIBITOR FOR USE IN ENHANCING THE ANTITUMOR EFFECT OF AN ANTITUMOR AGENT IN A PATIENT RENASCIENCE CO LTD (JP) 2019-03-20 EP disclosed
US-10092537-B2 Use for PAI-1 inhibitor RENASCIENCE CO., LTD. (JP) 2018-10-09 US disclosed
US-20160158188-A1 NOVEL USE FOR PAI-1 INHIBITOR RENASCIENCE CO., LTD. (JP) 2016-06-09 US disclosed
EP-2990057-A1 NOVEL USE FOR PAI-1 INHIBITOR Renascience Co., Ltd. (JP) 2016-03-02 EP disclosed
US-8415479-B2 Inhibitor of plasminogen activator inhibitor-1 RENASCIENCE CO., LTD. (JP) 2013-04-09 US disclosed
US-20110112140-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 RENASCIENCE CO., LTD. (JP) 2011-05-12 US disclosed
EP-2272822-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 Renascience CO., LTD. (JP) 2011-01-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110112140-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 SERPINE1, SERPINB1, SERPINC1 SERPINE1 1/4885POLB 2992/4885G6PD 493/4885
US-20160158188-A1 NOVEL USE FOR PAI-1 INHIBITOR SERPINE1, SERPINC1, SERPINB1 SERPINE1 1/4885POLB 2824/4885G6PD 387/4885
US-10092537-B2 Use for PAI-1 inhibitor SERPINE1, SERPINC1, SERPINB1 SERPINE1 1/4885POLB 2556/4885G6PD 254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.